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Abstract
Eight isolates submitted to CDC from 1989 to 2006 from clinical specimens were initially identified as members of the genus
Burkholderia based on preliminary cellular fatty acid analysis and/or 16S rRNA gene sequencing. With the recent descriptions
of the new species B. rhizoxinica and B. endofungorum, which are considered endosymbiotic bacteria in Rhizopus
microsporus fungi, we now identify seven of these clinical isolates as B. rhizoxinica and one as B. endofungorum based on
biochemical testing, 16s rRNA, and DNA-DNA hybridization results. We also further characterize these isolates by assessing
toxin production and/or by multiple locus sequence typing.
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Introduction
Recently, Burkholderia spp. have been described that are not only
endosymbionts in Rhizopus microsporus, a saprotrophic fungi, but are
also responsible for the production of the toxins rhizoxin and
rhizoninwhich had been previouslybelievedto have been produced
solely by the fungi [1,2,3]. Rhizoxin is a important virulence factor
for infection of plants by Rhizopus and has antimitotic activity
[4,5,6]. Rhizonin is a cyclopeptide exhibiting fatal hepatotoxic
effects [3,5,7,8]. Burkholderia rhizoxinica produces rhizoxin and is now
associated with the ability of Rhizopus to cause rice seedling blight.
Burkholderia endofungorum was recently shown to produce rhizonin.
Both bacteria appear to reside in the cytosol of the fungal cell [6,9].
Clinical isolates H2199 (Ohio - 2002), H3620 (New Mexico -
2005), H500 (California - 1997), G8810 (North Carolina - 1993),
G7344 (Oregon - 1992), H2592 (District of Columbia - 2003),
H3977 (South Dakota - 2006), and G4101 (New York - 1989) were
submitted to the CDC from 1989 to 2006 by various public health
agencies in the U.S. and placed in our archive. All but one were
isolated from blood specimens with the exception being H2592
which was from a wound. These isolates were obtained from five
adult males and three adult females. Later enquiry on the clinical
background of these isolates did not yield any further information.
Biochemical characterization was not able to provide identification;
however, cellular fatty acid analysis of H500, G7344, G8810 and
G4101 indicated profiles similar to that for Burkholderia pseudomallei
and/or the Burkholderia cepacia complex. Analysis of the 16S rRNA
gene sequences also indicated that these isolates were members of
the genus Burkholderia, but did not yield a specific identity.
Based on the new descriptions of B. rhizoxinica and B.
endofungorum, we re-examined the isolates in our archive using
standard biochemical testing, 16S rRNA gene sequencing and
DNA-DNA hybridization. We now identify these clinically derived
strains as either B. rhizoxinica or B. endofungorum. We also further
characterize them by cellular fatty acid analysis (CFA) and/or and
multiple locus sequence typing (MLST).
Materials and Methods
Biochemical testing was performed on all strains and cellular
fatty acid (CFA) analysis was performed on strains H500, G7344,
G8810 and G4101 as described by Weyant et. al. [10].
We performed DNA-DNA hybridization as previously de-
scribed [11]. In brief: Cells were harvested and lysed, and the
chromosomal DNA was isolated and purified. DNA from the type
strains of B. rhizonica (HKI 454
T) and B. endofungorum (HKI 456
T)
were labeled with [
32P]dCTP using a commercial nick translation
kit (Invitrogen Life Technologies, Carlsbad, CA) and tested for
reassociation to unlabeled DNA from the same strains (homolo-
gous reaction). Reassociation of B. rhizonica DNA was tested with
DNA from H3977 and H2199 and that of B. endofungorum was
tested with DNA from G4101. A reciprocal reaction using labeled
G4101 DNA was also performed. Relative binding ratios and
percent divergence were calculated as described previously [11].
DNA sequencing was performed using methods and primers as
previously described. In brief: whole cell suspensions of bacteria
were used for PCR. Bacteria were grown by plating one loop (1 ml)
of stock cell suspension (heavy suspension of Burkholderia spp. in
defibrinated rabbit blood, stored at 270uC until use) on trypticase
soy agar with 5% defibrinated sheep blood (SBA) (BBL
Microbiology systems, Cockeysville, MD) and incubating aerobi-
cally 1–2 days at 37uC. A single colony was suspended in 200 mlo f
10 mM Tris, pH 8.0 in a 1.5 ml Millipore 0.22 mm filter unit
(Millipore, Bedford, MA), heated at 95uC for 30 min, and
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(100 ml) contained 5 U of Expand DNA polymerase (Boehringer
Mannheim, Mannheim, Germany), 2 ml of DNA solution in H2O,
10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl2,
200 mM (each) dATP, dCTP, dGTP, and dTTP, and 0.4 mMo f
each primer. Reactions were first incubated for 5 min at 95uC.
Then, 35 cycles were performed as follows: 15 sec at 94uC, 15 sec
at 60uC, and 1 min and 30 sec at 72uC. Reactions were then
incubated at 72uC for an additional 5 min. PCR products were
purified with Qiaquick PCR purification kit (Qiagen, Valencia,
CA). Sequencing was performed using an Applied Biosystems
(ABI) BigDye terminator cycle sequencing ver 3.1 kit as per the
manufacturer’s instructions, except 0.25 ml of BigDye were used
instead of 8 ml (Applied BioSystems, Foster City, CA). Sequencing
products were purified by using Centri-Sep spin columns
(Princeton Separations, Adelphia, NJ), and were resolved using
an Applied Biosystems model 3130xl automated DNA sequencing
system (Applied Biosystems) [9,12,13,14]. Analysis was performed
using the Accelrys GCG package ver 10.3 (Accelrys, San Diego,
CA) and MEGA 3 as previously described [14,15].
The 16S rRNA gene sequences obtained for strains G7344,
G8810, H500, H2199, H2592, H3620, H3977 and G4101 were
deposited in GenBank (Supporting Information S1). Analysis of
16S rRNA sequences were performed as previously described
[13]. A reconstruction of the phylogenetic relationship of the
bacterial isolates by multi-locus sequence typing (MLST) based on
six gene loci (gltB, gmhD, lepA, lipA, ndh, and rhiE) was performed as
previously described [9] and sequences were deposited in
GenBank (Supporting Information S1).
The obtained dataset consisted of 3160 nucleotides including
710 variable sites, 263 of them being parsimony informative.
Phylogenetic analyses were carried out in a Bayesian and distance
matrix framework. For Bayesian analyses we employed the
GTR+I+G model of nucleotide evolution. Bayesian tree sampling
was performed using the MrBAYES 3.1.1 program [16,17]. Two
analyses including 500,000 generations each were run in parallel.
Four chains were run simultaneously. Trees were sampled every
100th generation. The first 3,000 generations were deleted as the
‘‘burn in’’ of the chain. The remaining trees were summarized as
50% majority rule consensus trees. Phylogenetic trees were
visualized using the program Treeview [18]. Neighbor joining
trees were constructed using MEGA version 3.1 [15]. Branch
support for NJ trees was obtained by performing 10000 bootstrap
replicates. The corresponding Burkholderia pseudomallei ST1 (BPS)
sequence was used as an outgroup to root the tree. For the
construction of phylogenetic networks with the neighbor-net
method we used the program SplitsTree version 4.8 [19].
For secondary metabolite analysis the bacterial strains were
cultured on nutrient agar plates at 30uC. After 3 days a single
colony was used to inoculate 1 ml TSB. After 2 days cultivation at
30uC and 120 rpm, 1 ml fresh TSB was added. After another 2
days cultivation, the grown culture was transferred to 20 ml TSB
and again incubated at 30uC (120 rpm) for 48 h. An aliquot of
5 ml was used to inoculate 100 ml of production medium (1%
corn starch, 0.5% glycerol, 1% gluten meal, 1% dried yeast, 1%
corn steep liquor, and 1% CaCO3, pH=6.5). Cultivation took
place at 30uC, 120 rpm, for 4 days.
Extraction and HPLC analysis was performed as described
previously [20].
Results
These eight clinical isolates shared common phenotypic charac-
teristics. They were nonmotile, gram-negative, coccobacilli. They
produced oxidase but did not produce catalase, indole, urease, did
not reduce nitrite, did not hydrolyze gelatin or esculin, and did not
utilize citrate. Nitrate was reduced by only one isolate H3977. No
acid production in the slant or butt of triple-sugar iron agar was
noted. There was no growth on MacConkey agar, Salmonella
Shigella agar or on cetrimide agar. No acid production was
observered in King’s oxidation-fermentation base from D-glucose,
D-xylose, mannitol, lactose, sucrose, and maltose. Variable
reactions were produced with litmus milk. We were unable to
demonstrate catalase production and motility with neither of these
clinical strains or with the type strains of B. rhizoxinica (HKI 454
T)
and B. endofungorum (HKI 456
T) in our laboratory even though these
characteristics were reported by Partida-Martinez and coworkers
[6]. Partida-Martinez and coworkers noted that growth of these
bacteria was poor in pure culture and did not allow for consistent
biochemical characteristics [6].
Analysis of the 16S rRNA gene sequences indicates that H2199,
H3620, H500, G8810, G7344, H2592, H3977 have .99.4%
identity to the 16S rRNA gene sequence for the B. rhizoxinica type
strain (HKI 454
T) and G4101 has an identity of 99.4% to the
sequence for the B. endofungorum type strain (HKI 456
T) (Figure 1).
Four strains were selected for cellular fatty acid analysis (CFA).
H500, G7344, G8810 and G4101 shared a unique profile which is
easily recognized by the presence of two cyclopropane acids
(17:0cyc, 19:0cyc11-12), 16:0 and 18:1w7c as major acids (8–
27%), and smaller amounts (1–5%) of six hydroxy acids (3-OH-
14:0, 2-OH-16:1, 2-OH-16:0, 3-OH-16:0, 2-OH-18:1, 2-OH-
19:0cyc). The CFA composition of H500, G7344, G8810 and
G4101 is consistent with that of the type strains of B. rhizoxinica and
B. endofungorum [6], and is most similar to that of the CFA group
containing B. cepacia, B. gladioli, B. mallei and B. pseudomallei [10].
The results of DNA relatedness studies are given in Table 1.
Isolates H3977 and H2199 exhibited greater than 78% relatedness
(RBR) under both the optimum and stringent reassociation criteria
and had divergence (D) of less than 5 to the labeled DNA from the
B. rhizoxinica type strain. Isolate G4101 exhibited 76% relatedness
under optimum criteria, but 69% under the more stringent
conditions when matched with labeled DNA from the B.
endofungorum type strain, however in the reciprocal reaction using
labeled G4101 the relatedness is over 70% for both the optimum
and stringent reassociation criteria.
The results of the MLST indicate that strains G8810, H2190,
H500, G7344, H2592, and H3620 are members of the B.
rhizoxinica clade called the ‘‘Pacific group’’ (97.7% to 99.4%
identity with B. rhizoxinica type strain), whereas isolate H3977 is
more remotely related to this group (95.9% identity) (Figure 2).
Strain H3977 is most likely not a member of the known subclades
and appears to be the only known member of a new group within
the complex. Alleles for isolate G4101 cluster closely with
Burkholderia spp. from the ‘‘Eurasian branch’’ of endofungal
symbionts (99.3% to 99.8% identity) and still has 95.7% identity
with the B. endofungorum type strain from Mozambique.
To verify the production of toxins by the clinical isolates the
metabolic profiles of two bacterial strains were investigated. Strain
H2199 and G7344 proved to be culturable under the conditions
optimized for rhizoxin formation whereas we were unable to grow
G4101 for the toxin study. HPLC and MS analyses clearly showed
that H2199 and G7344 produce high amounts of cytotoxic
rhizoxin analogues (Figure 3).
Discussion
Recently, the toxin rhizonin was shown to be produced by
endosymbiont B. endofungorum and not by the host Rhizopus [3]. It is
B rhizoxinica endofungorum from Clinical Specimens
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rhizonin, but the production of this toxin could be clinically
significant since rhizonin is a known hepatotoxin. Further studies
will determine if this strain produces rhizonin. However, in all
hitherto examined cases there has been no evidence for the
involvement of Burkholderia symbionts for the development of
zygomycoses [21,22].
The presence of an acyl transferase AT gene (rhiE) from the
rhizoxin biosynthesis gene cluster suggests that the clinical isolates
of B. rhizoxinica might have the capacity to produce cytotoxic
polyketides [23]. By metabolic profiling of the bacterial cultures,
we unequivocally showed that strains H2199 and G7344 produce
significant amounts of rhizoxin derivatives. The production of
rhizoxin could influence the course of human infection because the
toxin has anti-mitotic activity in mammalian cells and has
potential as an antitumor drug. Previous work has demonstrated
that derivatives of rhizoxin vary in anti-mitotic activity [20].
Further studies will indicate whether these isolates produce the
toxin or derivatives of the toxin.
We report for the first time that strains of B. rhizoxinica and B.
endofungorum have been associated with human clinical specimens.
Various Burkholderia spp. are known pathogens with B. pseudomallei
causing melioidosis and B. mallei causing glanders [13,24]. There
are also cases of opportunistic infection by less pathogenic
members of the Burkholderaea such as in the case of B. cepacia
infections, especially among cystic fibrosis patients, and infection
by B. thailandensis [25,26].
Since members of the B. rhizoxinica complex are known to form
tight associations with their host, fungal involvement is possible,
however there was no known detection of fungal infections in these
Figure 1. MEGA 3 analysis of 16S rRNA gene sequences using neighbor-joining and Kimura 2-parameter settings with 1000 step
bootstrap. Phylogenetic tree of Burkholderia rhizoxinica and B. endofungorum based on comparisons with 16S rDNA sequences of related bacteria.
Pseudomonas aeruginosa DSM 50071 (GenBank accession no. X06684) was used as an outgroup for this analysis. Bar, 2% sequence dissimilarity.
doi:10.1371/journal.pone.0015731.g001
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Labeled B. rhizoxinica HKI 454
T DNA
RBR @ 65uC D RBR @ 80uC
B. rhizoxinica HKI 454
T 100 0.0 100
H3977 83 0.0 84
H2199 85 2.5 79
Labeled B. endofungorum HKI 456
T DNA
RBR @ 65uC D RBR @ 80uC
B. endofungorum HKI 456
T 100 0.0 100
G4101 76 3.5 69
Labeled G4101 DNA
RBR @ 65uC D RBR @ 80uC
G4101 100 0.0 100
B. endofungorum HKI 456
T 82 0.1 72
RBR, relative binding ratio; D, percent divergence.
doi:10.1371/journal.pone.0015731.t001
Figure 2. Phylogenetic network of Burkholderia spp from. clinical isolates together with fungal symbionts (B1–B8) based on MLST
data. B1: Burkholderia rhizoxinica type strain. B5: B. endofungorum type strain. BPS: B. pseudomallei (outgroup).
doi:10.1371/journal.pone.0015731.g002
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incomplete and further enquiries did not prove productive. The
presence of the bacteria by contamination of the specimens cannot
be excluded. Seven of the isolates were derived from blood and
one from wound tissue. Since Rhizopus are ubiquitous and some
are opportunistic human pathogens, it is possible that the patients
were colonized by the fungi and that culturing was attempted only
to detect bacterial growth, thus missing the presence of Rhizopus
[27]. When B. rhizoxinica or B. endofungorum are detected in clinical
specimens, clinicians may wish to check for the presence of fungal
involvement.
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